web based nursing navigator programme
Behavioralhealth education guidance surveillance case management
NCT Number: NCT07014553
The aim of this project is to determine the effect of the Web-Based Nurse Navigation Program on breast cancer screening behaviors (mammography, BSE, CBE) in women at high risk of breast cancer. The program to be developed within the scope of the project is named as "Web-Based Nurse Navigation Program (WeT-HNP)", which reflects the web-based and navigation concepts.
This study is active but is not currently recruiting participants.
Notify Me30 year–70 year
Female
Interventional
Not applicable
Cancer early diagnosis screening and education center, Istanbul, Büyükçekmece, Turkey (Türkiye)
Breast cancer is a very important health problem affecting women's health in the world and in our country. It was reported that 685,000 people died of breast cancer in the world in 2020. The American Cancer Society estimates that approximately 310,720 new cases of invasive breast cancer will be detected in women in the United States in 2024, approximately 56,500 new cases of ductal carcinoma in situ (DCIS) will be detected, and approximately 42,250 women will die from breast cancer. In Turkey, breast cancer is the most common type of cancer in women and the cause of most deaths. In national reports for our country, it was reported that the frequency of breast cancer in women in 2018 was 48.6 per hundred thousand and the number of newly diagnosed patients in the same year was 22,500. Early diagnosis of breast cancer, which is a very important health problem in terms of women's health, reduces mortality and provides the opportunity for breast-conserving surgery. Today, the most effective approach in reducing mortality rates in breast cancer is early diagnosis/screening methods. Early diagnosis/screening methods aim to detect abnormal changes in women's breast tissue at an early stage. Breast self-examination (BSE), clinical breast examination (CBE) and mammography are widely recommended early diagnosis/screening methods for the early detection of breast cancer. In order to detect breast cancer at the earliest stage, it is recommended that women without symptoms in our country have a BSE every month starting at the age of 20, have a CBE once a year, and have a mammogram every 2 years between the ages of 40-69.It is recommended that women at high risk of breast cancer start breast cancer screening earlier and be monitored more frequently than women without symptoms. The American Cancer Society recommends that women at high risk of breast cancer have a mammogram every year after the age of 30.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
health education guidance surveillance case management
Time frame: baseline, 6 months
browsing behavior monitoring form
Time frame: baseline, 3 months
screening behaviors follow-up form
Time frame: baseline, 6 months
screening behaviors follow-up form
Time frame: baseline, 6 months
Breast Cancer Health Belief Model Scale Results
Time frame: baseline, 6 months
Breast Cancer Fear Scale
Time frame: baseline, 6 months
Mammography Competence Scale
Istanbul University - Cerrahpasa
Other
Acronym: WeT-HNP
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06773897
Breast Cancer, Breast Cancer Prevention
Piscataway, New Jersey, United States
View Trial DetailsNCT04265547
Breast Cancer Risk, Breast Diseases
New York, United States
View Trial DetailsNCT06722469
Breast Cancer Prevention, Breast Cancer Risk
View Trial DetailsNCT05848856
Arterial Occlusive Diseases, Arteriosclerosis
Palo Alto, California, United States
View Trial Details